XYKEN, LLC

McLean, VA

OncologyvaccinePhase II

What changed

Phase II trial registered: Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia

8mo agoTrial registeredNov 18, 2025Source filing (opens the source filing in a new tab)

Momentum

66no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R44 · $673k · non-dilutive
Apr 15, 2025
XYKEN, LLC · PI YI, STEVEN · NIDCD · award ends Mar 31, 2028 · Smartphone based custom-fit and low-cost hearing aids manufacturing system
NIH RePORTER · NIH RePORTER 11173541 (opens the source filing in a new tab)
Grant
R01 · $30k · non-dilutive
Dec 1, 2024
UT SOUTHWESTERN MEDICAL CENTER · PI KONOPKA, GENEVIEVE · NIMH · award ends Feb 28, 2027 · Cellular resolution multi-omics of white matter tracts in developing human and non-human primate brain for cell atlases-Diversity
NIH RePORTER · NIH RePORTER 11168653 (opens the source filing in a new tab)
Grant
R01 · $911k · non-dilutive
Sep 17, 2024
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOF, PATRICK R · NIA · award ends May 31, 2029 · Lifespan and Cardiovascular Health Effects on The Brain in Humans and Great Ape
NIH RePORTER · NIH RePORTER 11193426 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 10, 2024
T-LGL Leukemia, NK-LGL Leukemia · RECRUITING · sponsor: Institute of Hematology & Blood Diseases Hospital, China · Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
ClinicalTrials.gov · NCT06530576 (opens the source filing in a new tab)
Grant
R01 · $1.3M · non-dilutive
May 1, 2024
UT SOUTHWESTERN MEDICAL CENTER · PI KONOPKA, GENEVIEVE · NIMH · award ends Feb 28, 2027 · Cellular resolution multi-omics of white matter tracts in developing human and non-human primate brain for cell atlases
NIH RePORTER · NIH RePORTER 11083015 (opens the source filing in a new tab)
Grant
R01 · $643k · non-dilutive
Jun 15, 2021
UT SOUTHWESTERN MEDICAL CENTER · PI KONOPKA, GENEVIEVE · NIMH · award ends Apr 30, 2026 · Foxp-regulated signaling pathways in brain development
NIH RePORTER · NIH RePORTER 11121794 (opens the source filing in a new tab)
Grant
P40 · $61k · non-dilutive
Aug 15, 2017
UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HOPKINS, WILLIAM D · OD · award ends Apr 30, 2028 · Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR): Applied Research
NIH RePORTER · NIH RePORTER 11094005 (opens the source filing in a new tab)
Grant
P40 · $1.3M · non-dilutive
Aug 15, 2017
UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HOPKINS, WILLIAM D · OD · award ends Apr 30, 2028 · Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR)
NIH RePORTER · NIH RePORTER 11094001 (opens the source filing in a new tab)
Grant
P40 · $1.2M · non-dilutive
Aug 15, 2017
UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HOPKINS, WILLIAM D · OD · award ends Apr 30, 2028 · Specific Pathogen Free 18 Baboon Research Resource {(SPF18BRR): Resource Core
NIH RePORTER · NIH RePORTER 11094002 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator KONOPKA, GENEVIEVE is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the grant record at 0.23{"reasons":["no candidate cleared the review threshold"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
8mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
8mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH P40 · $0.1M · Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR): Applied Research
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH P40 · $1.3M · Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR)
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH P40 · $1.2M · Specific Pathogen Free 18 Baboon Research Resource {(SPF18BRR): Resource Core
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Foxp-regulated signaling pathways in brain development
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.9M · Lifespan and Cardiovascular Health Effects on The Brain in Humans and Great Ape
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $1.3M · Cellular resolution multi-omics of white matter tracts in developing human and non-human primate brain for cell atlases
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R44 · $0.7M · Smartphone based custom-fit and low-cost hearing aids manufacturing system
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.0M · Cellular resolution multi-omics of white matter tracts in developing human and non-human primate brain for cell atlases-Diversity
Jan 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R44 · $673k · non-dilutive

R01 · $30k · non-dilutive

R01 · $911k · non-dilutive

PHASE2 registered

R01 · $1.3M · non-dilutive

R01 · $643k · non-dilutive

P40 · $61k · non-dilutive

P40 · $1.3M · non-dilutive

P40 · $1.2M · non-dilutive